STRATEGIC NEWS WATCH — June 24, 2026
|
Novartis committing up to $1.9 billion to a discovery collaboration with Antares Therapeutics headlines a dealmaking-heavy session in which large-cap pharma is paying option-based premiums for pre-clinical platforms while European pricing pressure reshapes obesity-drug launch plans. Today’s top developments:
|
What to Watch
- Novartis / Antares targets — With Antares’ lead program expected to enter the clinic in 2026, watch which “undruggable” targets the partners disclose and whether Novartis exercises its options to license assets out of the up-to-$1.9 billion collaboration.
- Lilly BD momentum — Concurrent moves with Chai (AI discovery) and Abbisko (Asia-Pacific oncology) point to an accelerating externalization strategy; expect further partnership announcements out of BIO 2026 in the days ahead.
- EU drug-pricing pressure — Lilly’s MFN-driven launch caution and EFPIA’s access report, alongside the US probe of German pricing, intensify pressure on EU member states to raise what they pay for innovative medicines; watch for government signals on reimbursement reform.
- Bocunebart Phase 2b readout at EAN — Primary PROCEED data presented June 27–30 in Geneva will determine whether Lundbeck has a credible next-generation migraine asset and could prompt analyst pipeline re-rating.
- Regenxbio FDA filing — With confirmatory dosing complete, watch the agency’s reception of the planned Q3 2026 Duchenne BLA as a litmus test for how receptive current FDA leadership is to accelerated gene-therapy pathways.
This brief highlights the edition’s top stories. Read the full June 24, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.
